HC Wainwright Expects Lower Earnings for Viking Therapeutics

Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) - Analysts at HC Wainwright lowered their Q2 2025 earnings estimates for Viking Therapeutics in a research note issued on Thursday, April 24th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings of ($0.42) per share for the quarter, down from their previous forecast of ($0.35). HC Wainwright has a "Buy" rating and a $102.00 price objective on the stock. The consensus estimate for Viking Therapeutics' current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for Viking Therapeutics' Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.48) EPS and FY2025 earnings at ($1.76) EPS.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.10). During the same period in the prior year, the company earned ($0.26) EPS. The firm's quarterly revenue was up .0% compared to the same quarter last year.

A number of other analysts also recently issued reports on VKTX. The Goldman Sachs Group initiated coverage on shares of Viking Therapeutics in a report on Tuesday, April 8th. They set a "neutral" rating and a $30.00 price objective for the company. Cantor Fitzgerald raised shares of Viking Therapeutics to a "strong-buy" rating in a research note on Tuesday. Citigroup began coverage on shares of Viking Therapeutics in a research note on Friday, February 7th. They issued a "neutral" rating and a $38.00 price target for the company. Truist Financial reissued a "buy" rating and issued a $75.00 price target (down from $95.00) on shares of Viking Therapeutics in a research note on Monday. Finally, B. Riley reissued a "buy" rating and issued a $96.00 price target (down from $109.00) on shares of Viking Therapeutics in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating, ten have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $87.15.

Viking Therapeutics Stock Down 2.8 %

Shares of NASDAQ VKTX traded down $0.81 during mid-day trading on Monday, reaching $28.06. 2,026,130 shares of the company were exchanged, compared to its average volume of 4,088,963. Viking Therapeutics has a 52 week low of $18.92 and a 52 week high of $81.86. The stock has a market capitalization of $3.15 billion, a PE ratio of -28.02 and a beta of 0.84. The company's 50 day moving average price is $26.17 and its 200 day moving average price is $39.90.

Hedge Funds Weigh In On Viking Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. S.A. Mason LLC increased its position in shares of Viking Therapeutics by 20.0% during the fourth quarter. S.A. Mason LLC now owns 1,800 shares of the biotechnology company's stock valued at $72,000 after buying an additional 300 shares during the period. Blue Trust Inc. increased its position in shares of Viking Therapeutics by 75.9% during the fourth quarter. Blue Trust Inc. now owns 716 shares of the biotechnology company's stock valued at $29,000 after buying an additional 309 shares during the period. Bank Julius Baer & Co. Ltd Zurich increased its position in shares of Viking Therapeutics by 7.4% during the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 4,980 shares of the biotechnology company's stock valued at $221,000 after buying an additional 345 shares during the period. Arizona State Retirement System increased its position in shares of Viking Therapeutics by 1.2% during the fourth quarter. Arizona State Retirement System now owns 28,929 shares of the biotechnology company's stock valued at $1,164,000 after buying an additional 353 shares during the period. Finally, HighMark Wealth Management LLC increased its position in shares of Viking Therapeutics by 9.4% during the first quarter. HighMark Wealth Management LLC now owns 4,660 shares of the biotechnology company's stock valued at $113,000 after buying an additional 400 shares during the period. Hedge funds and other institutional investors own 76.03% of the company's stock.

Insider Activity

In related news, Director Sarah Kathryn Rouan purchased 1,240 shares of Viking Therapeutics stock in a transaction that occurred on Monday, March 31st. The shares were bought at an average price of $24.15 per share, for a total transaction of $29,946.00. Following the completion of the transaction, the director now directly owns 1,240 shares of the company's stock, valued at $29,946. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 4.10% of the company's stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.